University of Tennessee, Knoxville College of Nursing, Knoxville, and the Departments of Pediatrics, Health Policy, and Biostatistics, the Vanderbilt Center for Child Health Policy, and the Mildred Stahlman Division of Neonatology, Vanderbilt University Medical Center, Nashville, Tennessee.
Obstet Gynecol. 2023 Aug 1;142(2):339-349. doi: 10.1097/AOG.0000000000005227. Epub 2023 Jul 5.
To examine whether access to treatment for women with opioid use disorder (OUD) varied by race and ethnicity, community characteristics, and pregnancy status.
We conducted a secondary data analysis of a simulated patient caller study of buprenorphine-waivered prescribers and opioid-treatment programs in 10 U.S. states. We conducted multivariable analyses, accounting for potential confounders, to evaluate factors associated with likelihood of successfully securing an appointment. Descriptive statistics and significance testing examined 1) caller characteristics and call outcome by assigned race and ethnicity and clinic type (combined, opioid-treatment programs, and buprenorphine-waivered prescribers) and 2) clinic and community characteristics and call outcome by community race and ethnicity distribution (majority White vs majority Black, Hispanic, Asian, American Indian, Alaska Native, Native Hawaiian, or Pacific Islander) and clinic type. A multiple logistic regression model was fitted to assess the likelihood of obtaining an appointment by callers' race and ethnicity and pregnancy status with the exposure of interest being majority Black, Hispanic, Asian, American Indian, Alaska Native, Native Hawaiian, or Pacific Islander community distribution.
In total, 3,547 calls reached clinics to schedule appointments. Buprenorphine-waivered prescribers were more likely to be in communities that were more than 50% White (88.9% vs 77.3%, P<.001), and opioid-treatment programs were more likely to be in communities that were less than 50% White (11.1% vs 22.7%, P<.001). Callers were more likely to be granted appointments in majority Black, Hispanic, Asian, American Indian, Alaska Native, Native Hawaiian, or Pacific Islander communities (adjusted odds ratio [aOR] 1.06, 95% CI 1.02-1.10 per 10% Black, Hispanic, Asian, American Indian, Alaska Native, Native Hawaiian, or Pacific Islander community population) and at opioid-treatment programs (aOR 4.94, 95% CI 3.52-6.92) and if they were not pregnant (aOR 1.79, 95% CI 1.53-2.09).
Clinic distribution and likelihood of acceptance for treatment varied by community race and ethnicity distribution. Access to treatment for OUD remains challenging for pregnant people and in many historically marginalized U.S. communities.
考察在治疗接受度方面,女性阿片类药物使用障碍(OUD)是否存在种族和民族差异、社区特征差异和妊娠状况差异。
我们对在美国 10 个州开展的一项关于丁丙诺啡豁免处方医生和阿片类药物治疗项目的模拟患者来电者研究进行了二次数据分析。我们进行了多变量分析,考虑了潜在的混杂因素,以评估与成功预约可能性相关的因素。通过分配的种族和民族以及诊所类型(综合诊所、阿片类药物治疗项目和丁丙诺啡豁免处方医生),对来电者特征和来电结果进行描述性统计和显著性检验;通过社区种族和民族分布(白种人为主社区与黑种人、西班牙裔、亚洲人、美洲印第安人/阿拉斯加原住民、夏威夷原住民/太平洋岛民为主社区)和诊所类型,对诊所和社区特征与来电结果进行描述性统计和显著性检验。利用多项逻辑回归模型,评估种族和民族以及妊娠状况与感兴趣的暴露因素(黑种人、西班牙裔、亚洲人、美洲印第安人/阿拉斯加原住民、夏威夷原住民/太平洋岛民为主社区分布)之间的关联,以评估来电者获得预约的可能性。
共有 3547 个电话联系了诊所以预约。丁丙诺啡豁免处方医生更有可能在白种人比例超过 50%的社区(88.9% vs 77.3%,P<.001),而阿片类药物治疗项目更有可能在白种人比例低于 50%的社区(11.1% vs 22.7%,P<.001)。在黑种人、西班牙裔、亚洲人、美洲印第安人/阿拉斯加原住民、夏威夷原住民/太平洋岛民为主的社区(每 10%的黑种人、西班牙裔、亚洲人、美洲印第安人/阿拉斯加原住民、夏威夷原住民/太平洋岛民社区人口,调整后的优势比[aOR]1.06,95%置信区间[CI]1.02-1.10)以及在阿片类药物治疗项目(aOR 4.94,95%CI 3.52-6.92)就诊的来电者,获得预约的可能性更高,如果他们没有怀孕(aOR 1.79,95%CI 1.53-2.09)。
诊所分布和治疗接受程度因社区种族和民族分布而异。阿片类药物使用障碍的治疗机会仍然对孕妇和许多历史上处于边缘地位的美国社区具有挑战性。